Citi sees buying opportunity at AstraZeneca after recent falls
18th May 2026 11:21
(Sharecast News) - Analysts at Citi have reiterated a 'buy' rating on AstraZeneca and a 'neutral' on GSK following the European pharma sector's first-quarter earnings season.
Read moreGSK strikes agreement with China's SBP Group, launches final tranche of buyback programme
11th May 2026 08:07
(Sharecast News) - Drugmaker GSK said on Monday that it has struck an exclusive agreement with Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pharmaceutical to accelerate its chronic hepatitis B treatment, bepirovirsen, in mainland China.
Read moreSales jump at GSK on strong demand for specialty drugs
29th Apr 2026 08:18
(Sharecast News) - GSK posted above-forecast first-quarter profits on Wednesday, boosted by robust demand for its specialist HIV and oncology drugs.
Read moreGSK hepatitis B drug secures FDA priority review
28th Apr 2026 09:15
(Sharecast News) - Pharmaceutical giant GSK said on Tuesday that the US Food and Drug Administration had accepted its new drug application for bepirovirsen for priority review, with the drug being assessed as a potential treatment for adults with chronic hepatitis B.
Read moreUS court rules against GSK in dispute with AnaptysBio
27th Apr 2026 07:51
(Sharecast News) - A US court has granted a motion to dismiss filed by biotech AnaptysBio in a dispute with GSK's oncology unit, it was confirmed on Monday.
Read moreGSK's Blenrep gets green light from China's NMPA
20th Apr 2026 07:04
(Sharecast News) - Drugmaker GSK said on Monday that its relapsed/refractory multiple myeloma treatment Blenrep had received approval from China's National Medical Products Administration, making it the only anti-BCMA cleared for use in the country.
Read moreGSK ovarian, womb cancer drug posts positive results in early trial
13th Apr 2026 07:26
(Sharecast News) - GSK said its gynaecological cancer drug candidate had revealed positive results from early trials and would swiftly move to late-stage five clinical studies globally in the next few months.
Read moreGSK's Exdensur gets green light from Chinese regulator
8th Apr 2026 07:13
(Sharecast News) - Drugmaker GSK said on Wednesday that China's National Medical Products Administration has approved Exdensur as an add‑on therapy with intranasal corticosteroids for adults with chronic rhinosinusitis with nasal polyps who do not achieve adequate control with systemic steroids or surgery.
Read moreGSK submits bepirovirsen for EMA review after trials hit primary endpoints
27th Mar 2026 08:15
(Sharecast News) - Drugmaker GSK said on Friday that the European Medicines Agency will review its marketing authorisation application for the use of bepirovirsen, an investigational antisense oligonucleotide, in the treatment of adults with chronic hepatitis B.
Read moreLondon open: Stocks tumble as Middle East conflict escalates
23rd Mar 2026 08:32
(Sharecast News) - A GSK treatment for an aggressive form of small-cell lung cancer has been granted orphan drug designation in Japan, the pharma blue chip announced on Monday.
Read moreGSK's cholestatic pruritus treatment Lynavoy gets US FDA approval
19th Mar 2026 07:06
(Sharecast News) - GSK said on Thursday that the US Food and Drug Administration has approved its drug 'Lynavoy', or linerixibat, for the treatment of cholestatic pruritus in adults with primary biliary cholangitis, marking the first approved therapy in the US for the condition.
Read moreGSK secures Japan and China reviews for two late‑stage liver disease treatments
26th Feb 2026 07:46
(Sharecast News) - Drugmaker GSK said on Thursday that regulators in Japan and China had accepted two separate new drug applications for review, covering investigational treatments targeting chronic hepatitis B and cholestatic pruritus in primary biliary cholangitis.
Read moreGSK to acquire Canada's 35Pharma for $950m
25th Feb 2026 07:10
(Sharecast News) - Drugmaker GSK has agreed to acquire Canadian clinical-stage biopharmaceutical firm 35Pharma for $950m in cash.
Read moreGSK's Exdensur gets green light from European Commission
17th Feb 2026 08:31
(Sharecast News) - Drugmaker GSK said on Tuesday that the European Commission has approved its asthma and nasal polyps treatment Exdensur (depemokimab) for two separate indications.
Read moreChina's CDE accepts GSK's regulatory filing for RSV vaccine
10th Feb 2026 07:49
(Sharecast News) - Drugmaker GSK said on Tuesday that China's Center for Drug Evaluation has accepted its regulatory filing for Arexvy, its recombinant, adjuvanted respiratory syncytial virus vaccine, for the prevention of lower respiratory tract disease in adults aged 60 and over.
Read more